Teva's Multiple Sclerosis Pill Reduced Brain Lesions in Trial

By Alex Kuli

June 20 (Bloomberg) -- Teva Pharmaceutical Industries Ltd.'s experimental multiple sclerosis pill helped reduce brain lesions in a new study, moving the Israeli drugmaker closer to introducing the first oral treatment for the disabling disease.

Patients with the relapsing-remitting form of the illness on a daily dose of the medicine, laquinimod, had 40 percent fewer brain lesions than those on a placebo, according to the study in The Lancet medical journal. Lesions are caused when the immune system attacks the fatty tissue around nerve fibers, breaking the connection between brain and muscle.

» Read More